BioDelivery Sciences International Inc logo

BDSI - BioDelivery Sciences International Inc News Story

$3.07 -0.1  -3.5%

Last Trade - 2:45pm

Small Cap
Market Cap £227.2m
Enterprise Value £203.7m
Revenue £110.8m
Position in Universe 4065th / 6853

BRIEF-Endo and Biodelivery Sciences says pivotal data from two phase 3 trials showed safety and efficacy of Buprenorphine HCI buccal film for management of chronic pain

May 14 (Reuters) - Endo International PLC  ENDP.O : 
 * Endo pharmaceuticals and Biodelivery Sciences present pivotal data from two 
   phase 3 trials demonstrating safety and efficacy of buprenorphine hcl buccal 
   film for the management of chronic pain 
 * Statistically significant percent of patients on bema buprenorphine 
   experienced pain reductions of greater than 30 percent versus placebo 
 * Says overall, average pain scores increased more in the placebo arm versus 
   bema() buprenorphine at week 12 from baseline 
 * Source text for Eikon  ID:nPreGRn4sa  
 * Further company coverage  ENDP.O   
 ((Bengaluru Newsroom; +1 646 223 8780))
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.